Michael Heltzen

AI x enzymes = exozymes

[eXoZymes @eXoZymes]

From the @RollingStone magazine: The cannabis industry is entering its next evolution - shifting from commodity cultivation to the high-value race for rare cannabinoids, novel compounds and scalable biomanufacturing. The winners may not be the companies growing the most cannabis, but the ones that can engineer and manufacture the molecules nobody else can access. Companies like @eXoZymes are helping drive this shift by developing cell-free biomanufacturing platforms designed to produce rare (non-intoxicating) compounds with greater precision, scalability, and efficiency.

Read the full article here:
https://t.co/frBGR5tUv6 $EXOZ

[eXoZymes @eXoZymes]

Case study from @Springwise featuring Damien @Perriman: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturing.

@eXoZymes takes enzyme pathways from biology and brings them into the world of chemistry. @CaymanChemical is helping to scale this novel approach

Full case study available here:
https://t.co/qnPhYB8TEw $EXOZ

[eXoZymes @eXoZymes]

Biotech Bulls & Breakthroughs podcast: The Future of Biomanufacturing with Michael Heltzen

In this episode, John Gagliano of @BPharmCatalyst sits down with Michael @Heltzen, CEO of @eXoZymes, to discuss the revolutionary move toward cell-free biomanufacturing. Discover how eXoZymes is using AI to bypass the limitations of living cells, engineering "super-enzymes" through brute-force evolution, and bringing high-purity natural compounds like NCT to the mass market.

Full episode available here:
https://t.co/8TgCJJYJbP $EXOZ #exozymes #exozyme #biomanufacturing

[eXoZymes @eXoZymes]

Grow Everything podcast: In this episode, Damien Perriman, CCO of @eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules.

@Perriman states: “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.”

Full @messaginglab podcast episode available as both video and audio here:
https://t.co/ToVC42CtLa

#exozymes #cellfree #biomanufacturing $EXOZ

[eXoZymes @eXoZymes]

From The @villagevoice: The Metabolic Engine - How Scientists Are Exploring a New Path Beyond GLP-1 Weight-Loss Drugs

America’s weight-loss conversation has changed almost overnight. Prescription drugs once reserved for diabetes treatment are now household names, promising dramatic results on the scale. Many therapies currently available focus on reducing appetite or limiting calorie intake, which can certainly lead to weight loss. Yet those solutions often address the symptom rather than the deeper metabolic engine driving the condition.

Interest is growing around strategies that target the body’s internal energy system itself. Instead of simply telling the body to eat less, researchers are investigating ways to improve how the body burns energy, processes fat, and maintains metabolic balance. That shift in thinking has opened the door to a small but intriguing molecule known as N-trans-Caffeoyltyramine, or NCT.

Full story available here:
https://t.co/1KZ7d5eUMX

[Michael Heltzen @heltzen]

Looking good Damien!

You represent the NCT business oppertunity so well: The small molecule that boosts metabolism by turning fat into energy!

[eXoZymes @eXoZymes]

CCO at @eXoZymes, Damien Perriman, interviewed at @Nasdaq around our NCT project:

"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine."

#exozymes #exozyme #enzymes #enzyme #NCT #Nasdaq #ntranscaffeoyltyramine $EXOZ

[eXoZymes @eXoZymes]

$EXOZ management to host conference call today at 5:30 PM Eastern:
https://t.co/B0KaZWTAa5

Michael @Heltzen, CEO of @eXoZymes (Nasdaq: EXOZ), states, “We’ve moved beyond our ‘big idea’ potential and into execution - building differentiated assets and capabilities in a capital-efficient way that we believe sets us apart. We expect to see further value generating inflection points as programs like NCT and our cannabinoid initiatives continue to advance through commercialization milestones.”

Full press release on the investor call here:
https://t.co/X1On7hazj1

#exozymes #exozyme #enzymes #enzyme #biomanufacturing

[Michael Heltzen @heltzen]

I agree:
The next generation of #biomanufacturing is cellfree (not cell based fermentation!), and as controversial that is to people in #synbio, I would like to extend an invitation to anyone that got a “project stuck in the cells complexity/unwillingness to be a chemical factory” and/or “had a hard time scaling up the production” to have a conversation about it all.

[eXoZymes @eXoZymes]

We're featured in this brilliant National Lab of the Rockies (formerly NREL) piece on cell-free biomanufacturing:

“Cell-free biocatalysis for biomanufacturing - or cell-free biomanufacturing - essentially operates enzymatic cascades without the constraints of a living cell. This is a technology that could transform the bioenergy sector but also pharma and fine chemicals,” explained Yannick Bomble, an NLR principal scientist and an R&D leader in cell-free biomanufacturing.

Full story from @NatLabRockies available here:
https://t.co/ruRqJ8mPXp #exozymes #biomanufacturing #exozyme #NREL #NLR $EXOZ

[eXoZymes @eXoZymes]

As part of @Nasdaq's 'Amplify Spotlight' series, CEO of eXoZymes, Michael Heltzen (@heltzen), recently sat down with Michael B. Spector (@michaelbspector) from Nasdaq for a in-depth interview.

Heltzen states: "That's how we can run these simulations much much faster and much cheaper than anyone else and therefore it allows us to to brute force evolution."

Full interview available here:
https://t.co/8HMDGqhrUq

$EXOZ @NasdaqExchange #exozymes #exozyme #enzymes #enzyme

[eXoZymes @eXoZymes]

Advancing commercial readiness with profound production metrics on initial NCT pilot run: The pilot run achieved approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity at 100L scale.

Co-founder of @eXoZymes and VP of Development, Paul Opgenorth (@popgenorth), PhD, states: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend.”

Full story here:
https://t.co/jSYX94XOkV

#exozymes #enzymes #nutraceuticals #exozyme #biomanufacturing #enzyme

[Michael Heltzen @heltzen]

It's time for another Heltzen's Video Highlight: 2025 in Review and Looking Ahead! In this video, I'm having conversations with our CSO, Tyler, and our CCO, Damien, about what happened last year��and what we anticipate happening this year.

Full video available here:
https://t.co/9QPRlE5QSr

[Michael Heltzen @heltzen]

Here's another video update about what's going on at eXozymes, as seen from my perspective. The most important takeaway this month, is that we have the Q3 earnings call coming up this Thursday - you can sign up for that right here:
https://t.co/2S3cUgLpSD

#exozymes #exozyme #enzymes #enzyme #biomanufacturing #biosolutions

[eXoZymes @eXoZymes]

Good things are in motion. Our CEO @heltzen being interviewed by @michaelbspector at @Nasdaq today. $EXOZ

[eXoZymes @eXoZymes]

Recently, during the 'AI - A tool U.S. industrial biomanufacturing cannot ignore' panel discussion at the @Bio_Markets Innovations Midwest conference in Omaha, Nebraska, @eXoZymes VP of Business Development, Zachary Karl, PhD, stated:

"I feel we have a significant opportunity to create a system where scientists are supported by AI-enabled tools. I don't think AI is going to replace the scientists in this space - I think it's going to amplify what they can do."

Watch the entire World Bio Markets panel here:
https://t.co/sosPFSVrjD

#enzymes #exozymes #alphafold #LLM #AI #ML #artificialintelligence

[Michael Heltzen @heltzen]

RT @eXoZymes: Inside Biotech podcast interviews CEO, Michael @heltzen:

"It's very much our capabilities to pick the right enzymes and get…

[eXoZymes @eXoZymes]

Driving the cell-free revolution: @eXoZymes leaders join @TheBioMADE Leadership & Technical Committees. This underscores eXoZymes’ commitment to - and growing influence as a thought leader in - cell-free biomanufacturing.

Chief Commercial Officer at eXoZymes, Damien Perriman (@Perriman), states, "Being elected to the BioMADE Leadership Council is both an honor and a responsibility. This is a pivotal moment where cell-free biomanufacturing is stepping into the national spotlight. At eXoZymes, we believe our technology will be instrumental in driving the shift toward faster, more scalable, and more resilient biomanufacturing. I look forward to working with fellow council members to shape priorities that unlock real-world impact across industries - from fuels to functional ingredients.”

Co-founder and VP of Development, Dr. Paul Opgenorth (@popgenorth), states, “The Technical Committee is where the details of innovation become the standards that move an industry forward. I’m excited to play a role in defining a technical roadmap for developing and deploying cell-free enzyme pathways in the real world that can accelerate biosolution development cycles, remove the cell-based bottlenecks, and make a new generation of highly valuable natural product molecules commercially viable at scale.”

Full story here:
https://t.co/KrOEpsjLxj

#enzyme #syntheticbiology #biomanufacturing #biosolution #exozyme #cellfree #exozymes #enzymes #synbio

[Michael Heltzen @heltzen]

This is a new format where I want to - via video - communicate about what's going on in and around @eXoZymes: Communicate with you about what's going on over the last month, what are the things that are on my mind - and our team's mind - in regards to how we're making progress.

Other than news, I also want to do deeper dives into specific topics. I am super passionate about things like leadership principles, how you build a team of people that are both as individuals - but definitely also as a group - performing the very best.

Please stay tuned around once per month - and feel free to ask questions!

#exozymes #exozymes #enzymes #enzymes #biomanufacturing #synbio $EXOZ

[eXoZymes @eXoZymes]

“Some of the challenges in SynBio, are the costs and the timelines. Timeline-wise, it takes a while to engineer, as the DBTL (design-build-test-learn) cycles can be anywhere from months to years. And I've seen that firsthand as I was in that industry for years and years.“

- states VP of Business Development at eXoZymes, Zachary Karl, PhD, highlighting some of the challenges of the synthetic biology space - and why he jumped at the opportunity to join eXoZymes, back in September of 2023.

https://t.co/Oo2mDr0pR6

#exozymes #exozyme #enzymes #enzyme #synbio #syntheticbiology #biomanufacturing #BioInnovationsMidwest #BIMW25 $EXOZ

[Michael Heltzen @heltzen]

A big shout out to the @MDBCapital team! Your conference in Dallas, Texas was nothing less than amazing. We had such a good time being in front of all the great investors, many of them that supported @eXoZymes from the beginning of the IPO and all the way forward to now.

#exozymes #exozyme #enzymes #enzyme #cellfree